Pfizer Inc. (NYSE:PFE) is drawing income-focused investors as its dividend yield climbs above 7% following a recent share price decline. The pharmaceutical giant's stock has fallen, boosting the yield on its quarterly payout, while the company navigates a mixed regulatory and clinical landscape.
The FDA on Wednesday approved Ibrance (palbociclib) for a broader indication, allowing its use in combination with trastuzumab and endocrine therapy for adults with HR-positive, HER2-positive advanced or metastatic breast cancer after induction therapy. This approval, based on the PATINA trial involving 518 patients, demonstrated a 24% reduction in the risk of disease progression or death. However, overall survival data are not yet mature.
In contrast, Pfizer reported Monday that its antibody-drug conjugate sigvotatug vedotin, acquired through the Seagen acquisition, failed to meet the primary overall survival endpoint in a Phase 3 trial for previously treated metastatic non-squamous non-small cell lung cancer. The study did not show a statistically significant benefit over docetaxel, though a stronger trend was observed in patients who had received only one prior therapy. Pfizer plans to continue evaluating the drug in combination regimens, including with pembrolizumab in first-line NSCLC.
The divergent news has left the stock under pressure. Pfizer shares closed Wednesday at $24.04, down 2.75%, and were indicated at $24.09 in premarket trading Thursday. The stock has slid 7.3% from $25.92 on June 17 to $24.04 on June 24, with trading volume surging to about 196.6 million shares over June 22-24, more than six times the volume on June 17.
Pfizer's quarterly dividend of $0.43 per share, payable September 1 to holders of record July 24, equates to an annualized payout of $1.72. Based on Wednesday's close, the forward yield stands at approximately 7.15%. The company's 2026 adjusted diluted EPS guidance of $2.80 to $3.00 puts the payout ratio between 57% and 61%, underscoring the dividend's sustainability but also highlighting the gap between income and earnings growth.
The elevated yield is a result of the stock's decline rather than a dividend increase. Pfizer emphasized that the upcoming third-quarter payout will mark 351 consecutive quarterly dividends and reiterated its commitment to maintaining and gradually growing the dividend over time.
Pfizer's overall revenue guidance for 2026 stands at $59.5 billion to $62.5 billion, with adjusted EPS of $2.80 to $3.00. The company faces headwinds from a projected $1.5 billion decline in COVID-19 product revenue compared to 2025 and another $1.5 billion hit from product exclusivity losses. The Seagen acquisition was intended to bolster Pfizer's oncology pipeline amid these challenges, but the sigvotatug vedotin failure underscores the high-risk nature of ADC development.
Despite the setback, the Ibrance approval reinforces Pfizer's position in breast cancer treatment. The company noted that Ibrance is now the first and only CDK4/6 inhibitor approved for HR-positive metastatic breast cancer regardless of HER2 status. Investors will look for further updates when Pfizer reports second-quarter 2026 results on August 4.
